Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Total Debt: 2022-2024

Historic Total Debt for NewAmsterdam Pharma Co N.V (NAMS) over the last 3 years, with Dec 2024 value amounting to $37.5 million.

  • NewAmsterdam Pharma Co N.V's Total Debt rose 134.70% to $44.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.4 million, marking a year-over-year increase of 134.70%. This contributed to the annual value of $37.5 million for FY2024, which is 198.35% up from last year.
  • NewAmsterdam Pharma Co N.V's Total Debt amounted to $37.5 million in FY2024, which was up 198.35% from $12.6 million recorded in FY2023.
  • Over the past 5 years, NewAmsterdam Pharma Co N.V's Total Debt peaked at $37.5 million during FY2024, and registered a low of $3,888 during FY2022.
  • In the last 3 years, NewAmsterdam Pharma Co N.V's Total Debt had a median value of $12.6 million in 2023 and averaged $16.7 million.
  • Data for NewAmsterdam Pharma Co N.V's Total Debt shows a peak YoY spiked of 323,305.35% (in 2023) over the last 5 years.
  • Over the past 3 years, NewAmsterdam Pharma Co N.V's Total Debt (Yearly) stood at $3,888 in 2022, then spiked by 323,305.35% to $12.6 million in 2023, then soared by 198.35% to $37.5 million in 2024.